MindBio Therapeutics Corp. MBIO WF have started pre-screening for participant entry into phase 2 LSD-microdosing clinical trials. The clinical trials are a for take home use of MindBio's LSD-microdosing treatment. The initial phase 2a open label trial will assess the treatment in patients with major depressive disorder for 8 weeks.
MindBio's LSD-Microdosing clinical trials to date have yielded positive top line data such as improved quality of sleep including REM and total time of sleep and statistically significant enhancements in subjective feelings of "wellness", "creativity", "happiness", "social connectivity" and "energy". Participants in the LSD-Microdosing group also reported statistically significant feelings of being less "angry" and less "irritable".
Co-founder and CEO of MindBio Therapeutics Justin Hanka stated "We are excited to be progressing our LSD-Microdosing protocols through to phase 2 clinical trials in patients with major depressive disorder. The positive data we have collected to date is highly encouraging for targeting depressed patients with diminished mood and disrupted sleep".
Benzinga Cannabis Capital Conference
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
Photo: Benzinga edit with photos by fizkes and olesea vetrila on Shutterstock
Related News
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.